Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination.

Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination.

Vaccines are proving to be highly effective in controlling hospitalisation and deaths associated with SARS-CoV-2 infection but the emergence of viral variants with novel antigenic profiles threatens to diminish their efficacy. Assessment of the ability of sera from vaccine recipients to neutralise S...

Full description

Bibliographic Details
Main Authors: Chris Davis, Nicola Logan, Grace Tyson, Richard Orton, William T Harvey, Jonathan S Perkins, Guy Mollett, Rachel M Blacow, COVID-19 Genomics UK (COG-UK) Consortium, Thomas P Peacock, Wendy S Barclay, Peter Cherepanov, Massimo Palmarini, Pablo R Murcia, Arvind H Patel, David L Robertson, John Haughney, Emma C Thomson, Brian J Willett, COVID-19 DeplOyed VaccinE (DOVE) Cohort Study investigators
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2021-12-01
Series:PLoS Pathogens
Online Access:https://doi.org/10.1371/journal.ppat.1010022

Internet

https://doi.org/10.1371/journal.ppat.1010022

Similar Items